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Host defense responses against microbes are most often thought of in terms of effectors of microbial
destruction. However, recent evidence demonstrates that themore complex interactions between themicro-
biota and innate immune mechanisms, such as the inflammasome-mediated response, cannot be readily
explained within just the traditional paradigms of microbial killing mechanisms. In this review, the concepts
of both resistance and tolerance are applied to inflammasome-microbiota interactions, and the various phys-
iological consequences of this interplay, including roles in inflammation, tissue repair, tumorigenesis, and
metabolism, are discussed.Introduction: A Conceptual Framework for Host-
Microbiota Interactions
The defense response to microbes is assumed to be dependent
on the immune system, whose primary function is thought of as
the sensing and killing of microbes. If we confine ourselves to
host-pathogen interactions, this assumption may make sense.
However, host-microbial interactions are not limited to those of
a pathogenic nature. For example, the body surfaces of verte-
brates are colonized by diverse microbial communities called
the microbiota, the greatest densities of which are found in the
lower intestine (Berg, 1996). Here, the microbiota is composed
of trillions of microbes representing thousands of species, the
composition of which likely reflects the coevolution of host and
microbes to achieve a mutually beneficial relationship. The
host provides themicrobiota a niche with a stable nutrient supply
and a mode of transmission to ensure maintenance within the
host population. In turn, the microbiota performs essential func-
tions for several aspects of host physiology including metabolic,
digestive, and immune functions (Honda and Littman, 2012). As
pathogens do not differ intrinsically from symbionts in their ability
to activate immune mechanisms, it does not make sense to
describe host defenses solely in terms of killing mechanisms.
In fact, it is becoming clear that interactions between symbionts
and the immune system are needed to maintain homeostasis
(Cash et al., 2006; Ivanov et al., 2009; Kelly et al., 2004; Mazma-
nian et al., 2008; Rakoff-Nahoum et al., 2004). Thus, immune-
microbe interactions must provide other defense functions, in
addition to killing mechanisms, that enable a host to survive
pathogenic interactions and maintain symbiotic relationships.
Ecologists have long recognized that plant defenses against
their pests can be broken down into two distinct components,
resistance and tolerance (Caldwell et al., 1958; Schafer, 1971).
These can be readily applied to host-microbe interactions as
follows. Resistance works to directly attack microbes to block
invasion and eliminate the infection. Tolerance encompasses
mechanisms that limit the negative impact of infection on host
health (Ayres and Schneider, 2012; Medzhitov et al., 2012;
Ra˚berg et al., 2009; Schneider and Ayres, 2008). The conceptual
framework of resistance and tolerance has only been applied to
experimental studies of host-pathogen interactions (Ayres et al.,Ce2008; Ayres and Schneider, 2008, 2009; Ferreira et al., 2011;
Jamieson et al., 2013; Ra˚berg et al., 2009; Seixas et al., 2009),
but a closer examination of evolutionary theory suggests that it
will also aid in our understanding of host-symbiont relationships.
Resistance protects the host by having a negative impact on
microbial fitness and will generate a Red Queen effect that will
drive the escalation of antagonistic traits in both host and micro-
bial populations (Ra˚berg et al., 2009). By contrast, tolerance pro-
tects the host by having a neutral to positive impact on microbial
fitness (Ra˚berg et al., 2009). Thus, tolerance traits will not fuel an
arms race between host and microbe, but rather are predicted
to go to fixation within the host population and may help drive
host-symbiont coevolution (Roy and Kirchner, 2000).
Immune responses are almost inevitably defined in terms of
pathogen/disease resistance. Recent evidence has shown,
however, that several effects attributed to the activation of an
innate mechanism, the inflammasome, cannot be readily ex-
plained within the paradigm of immunity as effectors of microbial
destruction. This review focuses on recent progress in under-
standing the interactions between the intestinal microbiota and
the inflammasome and illustrates how incorporating the con-
cepts of both resistance and tolerance can provide a useful
framework to describe our interactions with symbiotic microbes.
Inflammasomes
A key orchestrator of innate immune responses is the inflamma-
some, which is a cytoplasmic multiprotein complex required for
activation of the CASPASE-1 (CASP1) protease and subsequent
maturation and secretion of the proinflammatory cytokines inter-
leukin-1b (IL-1b) and IL-18 (reviewed in von Moltke et al., 2013).
CASP1 can also initiate a rapid inflammatory cell death called py-
roptosis. Several distinct inflammasomes have been described
(Table 1), each of which contains a sensor protein of the
NLR (nucleotide-binding domain, leucine-rich repeat) or PYHIN
(PYRIN and HIN-200 domain-containing) protein superfamilies.
Upon receiving an appropriate activation cue, the inflammasome
sensor proteins recruit pro-CASP1 either directly via homotypic
binding of the CARD domains or indirectly through the PYHIN
via the adaptor protein ASC, which contains a PYHIN and a
CARD domain. The recruitment of CASP1 induces its maturationll Host & Microbe 14, November 13, 2013 ª2013 Elsevier Inc. 491
Table 1. NLR and Inflammasome Components Described in This Review
NLR or Inflammasome Component Stimulatory Cue/Function, Reviewed in von Moltke et al., 2013
NAIP5-NLRC4 Flagellin from bacteria expressing type 3/4 secretion systems (T3SS/T4SS)
NLRP3 Crystalline/particulate matter, ATP signaling via the P2X7 receptor, viral infections, bacterial and fungal
products, microbiota?
NLRP6 Microbiota?
NLRP12 Yersina? Microbiota? Host homeostasis?
CASPASE-1 Inflammasory caspase required for the proteolytic cleavage of pro-IL-1b and pro-IL-18
ASC Adaptor protein that facilitates indirect binding of CASPASE-1 to PYHIN-containing NLRs
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including pro-IL-1b and pro-IL-18. Recent evidence points to
the inflammasome as a critical mediator of gut homeostasis,
suggesting that there is crosstalk between the inflammasome
and the intestinal microbiota. Based on recent studies, I propose
that inflammasome-microbiota interactions form a complex
network of resistance and tolerance defense strategies that
have a profound impact on host physiologies.
Resistance and Tolerance of the Microbiota
The relative contributions of resistance and tolerance to defense
can be distinguished by examining the relationship between
host health and microbial levels (Ayres and Schneider, 2012;
Ra˚berg et al., 2009; Schneider and Ayres, 2008). Using these pa-
rameters, a dose response curve can be generated to determine
how changes in genetic and environmental properties of a host-
microbe system can influence defenses (Ayres and Schneider,
2012). Assuming vigor (health of the host when uncolonized) is
constant, changes in health as microbial levels change would
indicate changes in resistance (Figure 1A). Changes in health
without directly influencing microbial levels would alter the slope
of the curve and reflect changes in tolerance (Figure 1B). The
more shallow the slope, the more tolerant the host is to interac-
tions with a particular microbe. In addition to revealing changes
in tolerance of pathogenic interactions, monitoring changes in
the slope will reveal different ecological relationships between
a host and a given microbe, including symbiotic and commensal
microbial relationships (Schneider, 2011) (Figure 1C). Although
the complexity of the microbiota poses challenges in deter-
miningmicrobial levels, the integration of new experimental tools
including gnotobiotic mice and culture-independent approaches
into our studies will be important in defining themechanisms that
contribute to resistance and tolerance of the microbiota. Thus, it
is possible to monitor the impact of specific genetic deletions in
the host on specific components of the microbiota and to eval-
uate effects of different flora components and environmental
changes on the host.
The underlying mechanisms of tolerance have been proposed
by several recent reviews, primarily in the context of host-path-
ogen interactions, and are suggested to encompass processes
that protect against physiological damage by (1) limiting immu-
nopathology, (2) repairing damage, (3) detoxification of host
and microbial derived toxic compounds, and (4) maintaining
energy homeostasis (Ayres and Schneider, 2012; Medzhitov
et al., 2012; Ra˚berg et al., 2009; Schneider and Ayres, 2008).
The same logic can be applied to host-microbiota interactions.
The close proximity of an abundant microbial community to492 Cell Host & Microbe 14, November 13, 2013 ª2013 Elsevier Inc.host tissues poses serious challenges to the mucosal immune
system. The host must avoid mounting unnecessary immune
responses to the microbiota while remaining responsive to path-
ogenic threats. Mechanisms that regulate the induction, degree,
and duration of immune responses to minimize immunopa-
thology will contribute to host tolerance. Gut barrier mechanisms
including the epithelial layer and overlaying mucus sequester the
microbiota and, together with immune regulatory mechanisms,
prevent the induction of excessive localized and systemic
immune activation (Honda and Littman, 2012; Hooper, 2009).
Compromises in barrier integrity can result in immunopathology,
malnourishment, anemia, and dehydration driven by changes
in the distribution of the microbiota. Thus, repair mechanisms
will likely facilitate tolerance of the microbiota.
Host-microbe interactions can cause the release of host- and
microbial-derived toxic compounds that may induce damage
(Ferreira et al., 2011; Seixas et al., 2009). Lipopolysaccharide
(LPS), a toxin produced by Gram-negative bacteria that is
recognized by Toll-like receptor 4 (TLR4), is produced in large
quantities in the intestine. Host production of intestinal alkaline
phosphatase, a hydrolase that detoxifies LPS by dephosphory-
lation, makes it unrecognizable to TLR4 (Bates et al., 2007),
thereby reducing unnecessary immune induction and enhancing
tolerance.
Maintenance of energy homeostasis may also contribute to
host tolerance of the microbiota. Immune and inflammatory re-
sponses impose significant energetic costs on the host (Lazzaro
and Rolff, 2011). Sustained inflammatory responses triggered by
the microbiota can result in physiological damage resulting from
dysregulated energy allocation to fuel the host response. The
strong metabolic influence the intestinal microbiota has on the
host due to its role in energy harvesting and possible regulation
of appetite will also likely influence tolerance.
I have focused only on host-encoded tolerance mechanisms;
however, because of the implications tolerance mechanisms
have on the coevolution of host-microbe interactions, it is
likely that there will also be a selection for tolerance factors in
microbial populations. Indeed, the molecule polysaccharide A
(PSA) produced by the human symbiont Bacteroidetes fragilis
protects intestinal inflammation in a mouse model of Helico-
bacter hepaticus infection (Mazmanian et al., 2008). Similarly,
Bacteroidetes thetaiotaomicron reduces inflammation by pro-
moting nuclear export of RelA, the transcriptionally active sub-
unit of NF-kB, in a PPARg-dependent manner (Kelly et al.,
2004). The extent to which the microbiota affects host toler-
ance and inflammasome-microbiota interactions requires further
investigation.
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Figure 1. Health-by-Microbe Plots Reveal
How Inflammasome-Microbiota Crosstalk
Affects Resistance and Tolerance
(A–G) Assuming health of the host when un-
colonized/uninfected or vigor remains unchanged,
the contributions of resistance and tolerance to
host defense in any host-microbe system can
be established by determining the relationship
between host health and microbial colonization/
infection levels. (A) Resistance is the inverse of
microbial levels. Changes in health as microbial
levels change indicate changes in resistance
defenses. (B) Changes in health without directly
influencing microbial levels would alter the slope
of the curve and reflect changes in tolerance. The
more shallow the slope, the more tolerant the
host is to interactions with a particular microbe.
(C) Monitoring changes in tolerance will reveal
different ecological relationships between a host
and a given microbe. (D) NLRP6 deficiency de-
creases resistance against Prevotellaceae/TM7,
resulting in decreased health (spontaneous colitis).
Nlrp6/ mice are more susceptible to DSS- or
DSS/AOM-induced disease. Increased suscep-
tibility is associated with increased coloniza-
tion levels of Prevotellaceae/TM7, suggesting
decreased resistance. It is unclear how levels of
Prevotellaceae/TM7 respond to DSS or DSS/AOM
treatment, and curves were drawn based on the
assumption that the levels do not change. (E)
NAIP5-NLRC4 deficiency enhances tolerance of
E. coli O21:H+, as indicated by a shallower slope
than wild-type mice. (F) Inflammasome enhances
tolerance in response to gut injury and CAC, as
indicated by a less shallow slope than CASP1-
deficient animals. (G) Inflammasome-induced
anorexia can enhance tolerance by inducing stress
responses or reduce tolerance by creating trade-
offs with the microbiota.
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Maintenance of microbiota composition is essential for health,
and disruptions in this ecosystem (dysbiosis) are associated
with inflammatory pathologies (Round and Mazmanian, 2009).
Dysbiosis can trigger the virulence of microbiota constituents
called pathobionts: symbionts or commensals that are typically
harmless to the host but can become pathogenic when genetic
or environmental conditions in the host change (Chow and Maz-
manian, 2010). Based on this concept, I begin with an example of
inflammasome-mediated resistance. Flavell and colleagues
demonstrated that the inflammasome regulates microbiota-
induced inflammation by providing resistance against patho-
bionts, thereby preventing dysbiosis (Elinav et al., 2011). The
microbiota of NLRP6-, CASP1-, ASC-, and IL-18-deficientCell Host & Microbe 14, Nmice exhibit overgrowth of Prevotel-
laceae and TM7 bacteria. Nlrp6/
mice have increased intestinal production
of the chemokine CCL5 and develop
spontaneous colitis. Oral administration
of dextran sulfate sodium (DSS) causes
mucus erosion and cytotoxicity to colonic
epithelial cells facilitating decompartmen-
talization and translocation of the intesti-
nal microbiota to systemic sites (Okayasu
et al., 1990). Nlrp6/ mice are more
susceptibile to DSS-induced intestinal injury. Susceptibility is
transmissible, as wild-type mice cohoused with Nlrp6/ mice
became colonized with Prevotellaceae and TM7 and were
more susceptible to DSS. In contrast, Ccl5/ mice cohoused
with Nlrp6/ animals become colonized with Prevotellaceae
and TM7 but did not develop more severe colitis, suggesting
that disease pathogenesis is dependent in part on intestinal
CCL5 production. Antibiotic treatment reduced the levels of Pre-
votellaceae and TM7 colonization and colitis severity in Nlrp6/
mice, strengthening the correlation between Prevotellaceae and
TM7 colonization and disease severity (Elinav et al., 2011). Thus,
the NLRP6 inflammasome prevents dysbiosis and colitis by
providing resistance against procolitogenic microbes through
production of IL-18 (Figure 1D). While similar roles for NLRP6,ovember 13, 2013 ª2013 Elsevier Inc. 493
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dependent mechanism, in vivo biochemical evidence for this
inflammasome, and in fact all inflammasomes, is lacking.
Although inflammasome responses can provide resistance
against pathobionts, excessive inflammation generated by aber-
rant inflammasome activation can be pathological and can nega-
tively impact host tolerance. Inflammasome activation triggered
by dysbiosis induced systemic inflammation and negatively
influenced tolerance of pathobionts (Ayres et al., 2012). Chronic
ingestion of DSS typically induces a rapid, colitis-like disease in
mice. Administration of broad-spectrum antibiotics in addition to
DSS ameliorated colitis-like symptoms and instead triggered
sepsis (Ayres et al., 2012). Antibiotics induced the expansion of
a multi-drug-resistant E. coli O21:H+ pathobiont in the intestine
that infected extraintestinal tissues upon gut injury. Infection of
wild-type mice recapitulated the sepsis observed in antibiotic/
DSS-treated animals, demonstrating that E. coli O21:H+ is
sufficient to trigger sepsis. E. coli O21:H+ harbors a type
three secretion system and flagellin that activates the NAIP5-
NLRC4 inflammasome, and sepsis was attenuated in Naip5/,
Nlrc4/, Casp1/, and Il-1b/mice. Importantly, the attenua-
tion of sepsis in these mice was observed despite similar infec-
tion levels in tissues of mutant and wild-type mice, thus defining
inflammasome activation as having an adverse effect on toler-
ance (Figure 1E) (Ayres et al., 2012). Therefore, systemic spread
of E. coli O21:H+ induces aberrant activation of the NAIP5-
NLRC4 inflammasome, triggering IL-1b-mediated immunopa-
thology that the animals are unable to tolerate. Taken together,
the studies by Elinav et al. and Ayres et al. suggest that inflam-
masome-pathobiont interactions influence both resistance and
tolerance defenses and can have either beneficial or harmful
effects on host health.
Tissue Repair
The intestinal microbiota and enteric pathogens are separated
from body tissues by a single epithelial cell layer with a mucus
overlay, and repair mechanisms are crucial to limit pathologies
when the integrity of this barrier is compromised. Recognition
of commensal-derived ligands by Toll-like receptors is essential
for repair of DSS-induced tissue injury (Rakoff-Nahoum et al.,
2004), and recent evidence suggests that inflammasome-
microbiota interactions are important for repair. Casp1/,
Asc/, and Il-18/ mice exhibited greater disease severity,
barrier permeability, microbial translocation, and defective
epithelial cell proliferation when treated with DSS (Allen et al.,
2010; Dupaul-Chicoine et al., 2010; Zaki et al., 2010). Adminis-
tration of recombinant IL-18 to Casp-1/ mice reduced dis-
ease severity, supporting a crucial role for IL-18 in repair of
the epithelium (Dupaul-Chicoine et al., 2010; Zaki et al.,
2010). Damage to the intestinal epithelium subjects the host
to the possible invasion of pathobionts or other constituents
of the microbiota. Thus, inflammasome-dependent repair of
the epithelial barrier may enhance host tolerance by minimizing
the development of immunopathology, dehydration, electrolyte
imbalances, and anemia (Figure 1F). It is noteworthy that loss of
barrier integrity does not alter the actual number of microbes
in the host, but only their distribution (and consequences),
and therefore repair of the barrier may be considered a form
of tolerance.494 Cell Host & Microbe 14, November 13, 2013 ª2013 Elsevier Inc.Little is known about the role of the microbiota in the repair of
other tissues. Intriguingly, older studies have shown that germ-
free mice display impaired wound repair in the skin of mice
(Okada, 1994), and both conventional and germ-free rats
showed enhanced skin repair when exposed to S. aureus, but
not several other bacterial species (Levenson et al., 1983). It
will be important to explore the possible role of inflammasomes
in this and other tissue contexts.
Tumorigenesis
Recent studies have identified a negative regulatory role for the
inflammasome in the pathogenesis of colitis-associated colon
cancer (CAC). The azoxymethane (AOM)/DSS model couples
the methylation mutagenic activity of AOM with chronic inflam-
mation induced by repeated cycles of DSS treatment to cause
adenomas and adenocarcinomas. In the AOM/DSS model,
Casp-1/, Asc/, and Nlrp3/ mice have increased tumor
burdens and reduced levels of IL-18 and IFN-g (Allen et al.,
2010; Dupaul-Chicoine et al., 2010; Zaki et al., 2010). Similarly,
NLRP12 is important for attenuation of colonic inflammation
and tumorigenesis (Allen et al., 2012; Zaki et al., 2011). Assuming
microbial levels remain unchanged, these data would suggest
that protection against tumorigenesis is one manifestation of
tolerance enhancement by inflammasomes (Figure 1F). Chronic
inflammation triggered by constituents of the microbiota can
render mice more susceptible to tumorigenesis. For example,
colonic inflammation has been shown to trigger the expansion
of luminal levels of E. coli. Monocolonization of mice with themu-
rine commensal E. coliNC101 is associated with increased devel-
opment of invasive mucinous adenocarcinoma (Arthur et al.,
2012). NLRP6 also protects against tumorigenesis (Chen et al.,
2011;Normandet al., 2011), andHuet al. provided a link between
intestinal dysbiosis and tumorigenesis inNlrp6/mice, suggest-
ing that inflammasome-dependent resistance against the micro-
biota can also protect against cancer (Hu et al., 2013) (Figure 1D).
Mice deficient for CASP-12, a dominant-negative regulator of
CASP-1, exhibit increased epithelial cell proliferation upon DSS
treatment and develop much higher tumor burden than wild-
type mice in the AOM/DSS model (Dupaul-Chicoine et al.,
2010). In a mouse model of diethylnitrosamine (DEN)-induced
hepatocarcinogenesis, defective NF-kB activation results in sus-
tained tissue renewal processes driven by JNK-dependent hepa-
tocyte proliferation, resulting in carcinogenesis (He et al., 2010).
Tumorigenesis in some cases may therefore be a consequence
of normal tolerance mechanisms operating in the context of
chronic inflammation, exacerbated by extensive mutagenesis
(AOM, DEN) and cycles of tissue damage and repair.
Energy Homeostasis and Metabolism
The immune system and host metabolism are highly integrated,
and inflammasome-dependent resistance against commensals
also confers protection against the pathogenesis of metabolic
diseases. Asc/mice harbor a dysbiotic flora, and both Asc/
and Casp-1/ mice are more susceptible to developing diet-
induced nonalcoholic fatty liver disease (NAFLD) (Henao-Mejia
et al., 2012). Consistent with this, Nlrp3/ and Il-18/ mice
similarly develop more severe disease, suggesting that the
NLRP3 inflammasome (including ASC and CASP1) and IL-18
confer protection against disease pathogenesis. The dysbiotic
Cell Host & Microbe
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ligands in the gut and liver, resulting in TLR4- and TLR9-depen-
dent TNFa production. Critically, disease susceptibility is trans-
missible, as cohousing with Casp-1/, Nlrp3/, Nlrp6/, or
Il-18/ mice rendered wild-type mice more susceptible to
NAFLD. Furthermore, antibiotic treatment of Asc/ reduced
disease severity (Henao-Mejia et al., 2012), suggesting that
constituents of the dysbiotic flora found in these deficient mice
contribute to disease pathogenesis. Thus, Nlrp3- and Nlrp6-
dependent production of IL-18 can negatively regulate the
pathogenesis of NAFLD by providing resistance against the mi-
crobiota, creating a dose response curve similar to Figure 1D. It
remains to be determined if Nlrp3/, Nlrp6/, Casp-1/, and
Il-18/mice exhibit similar alterations in diet-dependent micro-
biota compositions as Asc/ mice and what microbial species
are the causative agents of disease in this context. This would
allow for formal testing of whether the effects are due to an
inflammasome-mediated tolerance mechanism.
Specific microbiota compositions are suggested to be more
efficient at energy harvesting than others and contribute to
the development of metabolic pathologies. Twin studies in lean
and obese subjects suggest that phylum-level changes and
decreased diversity of the microbiota are associated with
obesity (Turnbaugh et al., 2009). Whether dysbiotic floras asso-
ciated with inflammasome deficiencies have differences in en-
ergy harvest potential remains to be shown. However, both the
inflammasome and microbiota can regulate homeostatic appe-
tite and feeding efficiency, thus affecting energy balance. Central
and peripheral IL-18 suppresses feed efficiency in mice, and
Il-18/ mice exhibit hyperphagic behavior and develop obesity
(Netea et al., 2006; Zorrilla et al., 2007). The increased suscep-
tibility of developing NAFLD in inflammasome-deficient mice
(Henao-Mejia et al., 2012) could be explained in part by
hyperphagic behavior triggered by the expansion of specific
constituents of the microbiota, suggesting that inflammasome-
dependent resistance against the microbiota impacts feeding
behavior. Alternatively, inflammasome activation by compo-
nents of the microbiota could downregulate energy consump-
tion, resulting in enhanced tolerance of the microbiota.
Infections lead to sickness-induced anorexia and fever, which
influence energy homeostasis. Administration of IL-1b to animals
is sufficient to trigger these responses in the absence of infec-
tions (Hart, 1988), suggesting a role for the inflammasome in
these changes. Pathobiont-induced activation of the inflamma-
some in mice results in IL-1b-dependent changes in thermoreg-
ulation (Ayres et al., 2012). It has recently been proposed that
limiting food consumption and alterations in body temperature
may be evolved behavioral strategies to enhance tolerance by
promoting stress responses in vital tissues (Medzhitov et al.,
2012). In support of this, in Drosophila, anorexia confers toler-
ance to Salmonella Typhimurium infection (Ayres and Schneider,
2009). In addition, heat shock protects cells against TNF-
induced killing and arrests TNF secretion by inflammatory T
lymphocytes (Gromkowski et al., 1989). However, tolerance of
the pathobiont E. coli O21:H+ is compromised by activation of
the NAIP5/NLRC4 inflammasome despite body temperature
changes in response to infection (Ayres et al., 2012). This sug-
gests that the potential beneficial effects of sickness-induced
behaviors on host defenses are context dependent.CeAnorexia induced by inflammasome-microbiota interactions
could have complicated effects on tolerance of the microbiota.
Reduced food intake may trigger stress responses that can pro-
mote tolerance (Ayres and Schneider, 2009; Medzhitov et al.,
2012) (Figure 1G). However, when energy consumption be-
comes very low, it could create trade-offs between the micro-
biota and the host (Figure 1G). A host has finite energy levels
and the energetic demands of the microbiota must be satisfied
by this supply. When food is available, the microbiota tap into
this supply to fulfill energetic requirements. When food is scarce,
however, the symbiotic host-microbe relationship can turn para-
sitic, resulting in trade-offs as the microbiota is forced to extract
energy from its host. Indeed, two recent studies have demon-
strated that the intestinal microbiota can exacerbate the effects
of severemalnutrition in children (Smith et al., 2013; Trehan et al.,
2013). The mechanisms that dictate whether anorexia will have a
positive or negative influence on tolerance are unknown, but the
composition of the microbiota will likely affect the physiological
outcome. In a recent study of twins discordant for Kwashiorkor,
a severe form of malnutrition, Smith et al. implicated specific
dysbiotic flora as a causal factor for developing the condition
(Smith et al., 2013). This likely reflects the different metabolic
capabilities ofmembers of themicrobiota and the ability to adapt
to changes in the nutrient status of the host. For example, when
polysaccharides are limiting, Bacteroides thetaiotaomicron
changes its foraging behavior and metabolizes host mucus gly-
cans (Sonnenburg et al., 2005). Dysregulation of energy alloca-
tion to the microbiota can negatively impact host tolerance and
result in severe pathologies such as wasting syndrome, the pro-
gressive loss of body mass (Delano and Moldawer, 2006). Dra-
matic metabolic reorganizations are a common theme in the
pathogenesis of many infectious and inflammatory conditions
(Delano and Moldawer, 2006). These changes most likely reflect
the costs that inflammatory and immune responses impose on
the host, with the most significant cost likely being energetic
(Ayres and Schneider, 2012).
Based on these considerations, we can expect there to be
a ‘‘flip side’’ to inflammasome-mediated effects on metabolism.
Recent studies have implicated inflammasome activation in
insulin resistance and obesity. Nlrp3/, Asc/, and Casp1/
mice are protected from insulin resistance and glucose intoler-
ance induced by high-fat diet (HFD) (Stienstra et al., 2010,
2011; Vandanmagsar et al., 2011; Wen et al., 2011). By contrast,
two other studies reported no difference between weight gain in
Nlrp3/ mice and wild-type mice (Vandanmagsar et al., 2011;
Wen et al., 2011). The observed disparity is likely due to differ-
ences in the microbiota of the animals used. However, the
involvement of microbiota in these models remains to be tested.
Given extensive evidence that the effects of HFD-induced
obesity are influenced by the microbiota, a dependency on the
crosstalk between the NLRP3 inflammasome and the intestinal
flora for obesity pathogenesis would not be surprising. There-
fore, the microbiota-inflammasome crosstalk may have a nega-
tive impact on host health via activity of the Nlrp3 inflammasome
and generate a tolerance curve as in Figure 1E.
Open Questions and Future Perspectives
It is clear that microbiota-inflammasome interactions have a
broad impact on host physiologies. These effects cannot bell Host & Microbe 14, November 13, 2013 ª2013 Elsevier Inc. 495
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the concepts of both resistance and tolerance in our studies by
measuring both health and microbe levels. We must identify the
relevant microbial constituents that contribute to the physiolog-
ical consequences resulting from inflammasome-microbiota
interplay and determine if this is due to changes in tolerance or
resistance. We then can resolve questions in molecular terms:
How does the inflammasome regulate microbiota composition
via IL-18 and other mechanisms? What are the mechanisms
that drive the physiological consequences of inflammasome-
associated dysbiotic flora? What are the microbiota-associated
stimulatory cues that trigger inflammasome activation, and what
are the downstreammechanisms that impact host physiologies?
It will also be important to determine the consequences of inflam-
masome-microbiota interactions at other barriers of thebody.We
can then begin to investigate if manipulation of inflammasome-
microbiota interactions can be used as potential therapeutics
for pathologies associated with the associated pathologies.
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